Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.06.19
Views: 573

Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy

Dr Alessandra Tedeschi speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the results of the five-year follow up of the RESONATE-2 trial, where patients received ibrutinib as first-line treatment for chronic lymphocytic leukaemia (CLL).

She reports that the trial found improvements in PFS and OS for patients treated with ibrutinib, and the treatment was well tolerated.

Dr Tedeschi explains that this is significant as it can provide an alternative to chemotherapy, particularly for elderly patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.


· EHA 2019

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation